Abstract
Purpose
Fotemustine is a nitrosourea compound used for the treatment of malignant gliomas, especially in France. Recently, an EORTC-NCIC study has shown that a concomitant combination of radiotherapy plus temozolomide (an oral cytotoxic drug) improved survival in glioblastoma patients. We set out to test a concurrent combination of radiotherapy and fotemustine for newly malignant gliomas.
Methods
A prospective single-center phase II study opened for accrual in September 2004. Patients over 18 years of age able to give informed consent and with histologically proven, newly diagnosed supratentorial malignant gliomas were eligible. All patients were treated by a standard cranial irradiation (conformal irradiation, tumor bulk plus a margin of 2.5 cm) and concomitant daily administration of 10 mg/m2 of fotemustine (5 days per week, 6 weeks, 1 h 30 min before radiation therapy). Adjuvant chemotherapy, fotemustine, was administered at tumor progression as standard and classic regimen.
Results
Twenty-two patients were enrolled, 16 men and 6 women, median age 56 years (range 32–74), median Karnofsky performance status 70 (range 60–90). Histology included 16 glioblastomas, 3 anaplastic astrocytomas, 2 anaplastic oligodendrogliomas and 1 mixed glioma. Eight patients underwent surgery (three total resections). Fourteen patients had a stereotactic biopsy. The concurrent radiotherapy–fotemustine combination was well tolerated: toxicity was mild and three hematologic toxicities grade 3–4 were observed. Median survival from the initial diagnosis was 9.9 months, two patients are currently alive. Median survival was 11 months for surgery and 9 months for stereotactic biopsy.
Conclusions
Concomitant radiotherapy–fotemustine combination is safe and well tolerated. Overall survival of over 10 months for the whole population compares favorably with other reports.
This is a preview of subscription content, log in via an institution to check access.
References
Behin A, Hoang-Zuan K, Carpentier A et al (2003) Primary brain tumors in adults. Lancet 361:323–331
De Angelis LM (2001) Brain tumors. N Eng J Med 344:114–123
Fine HA, Dears KBG, Loeffler JS et al (1993) Meta-analysis of radiation with and without chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597
Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018
Stupp R, Hegi M, Gilbert M et al (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136
Beauchesne P, Pourchet J, Dore JF et al (2007). Effect on human malignant glioma cell lines and glioma xenografts of anti-neoplastic agents combined with low radiation doses. In: Proceedings AACR 2007, p 5058 (abstract)
Deloffre P, Paraire M, Bizzari JP (1990) Muphoran (fotémustine), une nouvelle nitrosourée : études précliniques. Cancer Commun 4:7–16
Fischel JL, Formento P, Etienne MC et al (1990) In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol 25:337–341
Filippeschi S, Colombo T, Bassini D et al (1998) Antitumor activity of the novel nitrosourea S 10036 in rodent tumors. Anticancer Res 8:1351–1354
IRIS Cancer Treatment Division (1999) Fotemustine Investigator’s Brochure. Version No. 3, September 15
Frenay M, Giroux B, Khoury S et al (1991) Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 27A:852–856
Silvani A, Lamperti E, Gaviani P et al (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neuro-Oncol 87:143–151
Ozkan M, Altinbas M, Er O et al (2004) Post-operative sequential chemo-radiotherapy in high grade cerebral gliomas with fotemustine. J Chemother 16:298–302
Frenay M, Lebrun C, Lonjon M et al (2000) Up-front chemotherapy with fotemustine/cisplatin/etoposide regimen in the treatment of 33 non-removable glioblastomas. Eur J Cancer 36:1026–1031
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Athanassiou H, Synodinou M, Maragoudakis E et al (2005) Randomised phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23:2372–2377
Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neur-oncol 5:79–88
Buckner JC, Ballman KV, Michalak JC et al (2006) Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93–72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24:3871–3879
Curran WJ, Scott JB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710
Scott CB, Scarantino C, Urtasun R et al (1998) Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90–06. Int J Radiat Oncol Biol Phys 40:51–55
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beauchesne, P.D., Taillandier, L., Bernier, V. et al. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study. Cancer Chemother Pharmacol 64, 171–175 (2009). https://doi.org/10.1007/s00280-009-0993-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-0993-x